Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients

Research output: Journal article (peer-reviewed)Journal article

7 Citations (Scopus)

Abstract

Vaccination is the primary public health strategy to cope with the COVID-19 pandemic. Although solid tumor and hematologic patients are at higher risk of serious COVID-19-related complications, data on immune responses to COVID-19 vaccines in this patient cohort are particularly scarce. The present study, therefore, aimed at the standardized determination of anti-SARS-CoV-2 spike protein antibody titers among non-vaccinated versus vaccinated solid tumor and hematologic patients who are under clinical observation or under treatment at the University Hospital Krems. Standardized anti-SARS-CoV-2 S antibody titers of a total of 441 patients were retrospectively analyzed. Our results show that antibody titers against the SARS-CoV-2 spike protein are significantly higher in solid tumor versus hematologic patients. While SARS-CoV-2 antibody titers were equal among sexes, an age-dependent decrease was observed. Of note, our studies additionally show that complete vaccination represents a valuable predictor for high anti-SARS-CoV-2 antibody responses in solid tumor and hematologic patients. In summary, to date, this is one of the largest studies to comprehensively evaluate the impact of various COVID-19 vaccines on anti-SARS-CoV-2 S antibody production in solid tumor and hematologic patients. Our findings aim to support future vaccination strategies in these highly vulnerable patients, including vaccination booster programs and alternative protective approaches.

Original languageEnglish
Article number4312
JournalCancers
Volume13
Issue number17
DOIs
Publication statusPublished - 26 Aug 2021

Keywords

  • Antibody response
  • COVID-19
  • Cancer patients
  • SARS-CoV-2
  • SARS-CoV-2 S vaccine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients'. Together they form a unique fingerprint.

Cite this